Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules

M. Ahn, S. R. Witting, R. Ruiz, Romil Saxena, Nuria Morral

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

RNA interference (RNAi) has become the cornerstone technology for studying gene function in mammalian cells. In addition, it is a promising therapeutic treatment for multiple human diseases. Virus-mediated constitutive expression of short hairpin RNA (shRNA) has the potential to provide a permanent source of silencing molecules to tissues, and it is being devised as a strategy for the treatment of liver conditions such as hepatitis B and hepatitis C virus infection. Unintended interaction between silencing molecules and cellular components, leading to toxic effects, has been described in vitro. Despite the enormous interest in using the RNAi technology for in vivo applications, little is known about the safety of constitutively expressing shRNA for multiple weeks. Here we report the effects of in vivo shRNA expression, using helper-dependent adenoviral vectors. We show that gene-specific knockdown is maintained for at least 6 weeks after injection of 1×10 11 viral particles. Nonetheless, accumulation of mature shRNA molecules was observed up to weeks 3 and 4, and then declined gradually, suggesting the buildup of mature shRNA molecules induced cell death with concomitant loss of viral DNA and shRNA expression. No evidence of well-characterized innate immunity activation (such as interferon production) or saturation of the exportin-5 pathway was observed. Overall, our data suggest constitutive expression of shRNA results in accumulation of mature shRNA molecules, inducing cellular toxicity at late time points, despite the presence of gene silencing.

Original languageEnglish
Pages (from-to)1483-1497
Number of pages15
JournalHuman Gene Therapy
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Small Interfering RNA
RNA Interference
Karyopherins
Gene Knockdown Techniques
Technology
Poisons
Viral DNA
Gene Silencing
Virus Diseases
Hepatitis B
Innate Immunity
Hepacivirus
Virion
Interferons
Cell Death
Therapeutics
Viruses
Safety
Injections
Liver

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules. / Ahn, M.; Witting, S. R.; Ruiz, R.; Saxena, Romil; Morral, Nuria.

In: Human Gene Therapy, Vol. 22, No. 12, 01.12.2011, p. 1483-1497.

Research output: Contribution to journalArticle

@article{00b130a916804f5dab941e1b87bf4c43,
title = "Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules",
abstract = "RNA interference (RNAi) has become the cornerstone technology for studying gene function in mammalian cells. In addition, it is a promising therapeutic treatment for multiple human diseases. Virus-mediated constitutive expression of short hairpin RNA (shRNA) has the potential to provide a permanent source of silencing molecules to tissues, and it is being devised as a strategy for the treatment of liver conditions such as hepatitis B and hepatitis C virus infection. Unintended interaction between silencing molecules and cellular components, leading to toxic effects, has been described in vitro. Despite the enormous interest in using the RNAi technology for in vivo applications, little is known about the safety of constitutively expressing shRNA for multiple weeks. Here we report the effects of in vivo shRNA expression, using helper-dependent adenoviral vectors. We show that gene-specific knockdown is maintained for at least 6 weeks after injection of 1×10 11 viral particles. Nonetheless, accumulation of mature shRNA molecules was observed up to weeks 3 and 4, and then declined gradually, suggesting the buildup of mature shRNA molecules induced cell death with concomitant loss of viral DNA and shRNA expression. No evidence of well-characterized innate immunity activation (such as interferon production) or saturation of the exportin-5 pathway was observed. Overall, our data suggest constitutive expression of shRNA results in accumulation of mature shRNA molecules, inducing cellular toxicity at late time points, despite the presence of gene silencing.",
author = "M. Ahn and Witting, {S. R.} and R. Ruiz and Romil Saxena and Nuria Morral",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/hum.2010.234",
language = "English",
volume = "22",
pages = "1483--1497",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules

AU - Ahn, M.

AU - Witting, S. R.

AU - Ruiz, R.

AU - Saxena, Romil

AU - Morral, Nuria

PY - 2011/12/1

Y1 - 2011/12/1

N2 - RNA interference (RNAi) has become the cornerstone technology for studying gene function in mammalian cells. In addition, it is a promising therapeutic treatment for multiple human diseases. Virus-mediated constitutive expression of short hairpin RNA (shRNA) has the potential to provide a permanent source of silencing molecules to tissues, and it is being devised as a strategy for the treatment of liver conditions such as hepatitis B and hepatitis C virus infection. Unintended interaction between silencing molecules and cellular components, leading to toxic effects, has been described in vitro. Despite the enormous interest in using the RNAi technology for in vivo applications, little is known about the safety of constitutively expressing shRNA for multiple weeks. Here we report the effects of in vivo shRNA expression, using helper-dependent adenoviral vectors. We show that gene-specific knockdown is maintained for at least 6 weeks after injection of 1×10 11 viral particles. Nonetheless, accumulation of mature shRNA molecules was observed up to weeks 3 and 4, and then declined gradually, suggesting the buildup of mature shRNA molecules induced cell death with concomitant loss of viral DNA and shRNA expression. No evidence of well-characterized innate immunity activation (such as interferon production) or saturation of the exportin-5 pathway was observed. Overall, our data suggest constitutive expression of shRNA results in accumulation of mature shRNA molecules, inducing cellular toxicity at late time points, despite the presence of gene silencing.

AB - RNA interference (RNAi) has become the cornerstone technology for studying gene function in mammalian cells. In addition, it is a promising therapeutic treatment for multiple human diseases. Virus-mediated constitutive expression of short hairpin RNA (shRNA) has the potential to provide a permanent source of silencing molecules to tissues, and it is being devised as a strategy for the treatment of liver conditions such as hepatitis B and hepatitis C virus infection. Unintended interaction between silencing molecules and cellular components, leading to toxic effects, has been described in vitro. Despite the enormous interest in using the RNAi technology for in vivo applications, little is known about the safety of constitutively expressing shRNA for multiple weeks. Here we report the effects of in vivo shRNA expression, using helper-dependent adenoviral vectors. We show that gene-specific knockdown is maintained for at least 6 weeks after injection of 1×10 11 viral particles. Nonetheless, accumulation of mature shRNA molecules was observed up to weeks 3 and 4, and then declined gradually, suggesting the buildup of mature shRNA molecules induced cell death with concomitant loss of viral DNA and shRNA expression. No evidence of well-characterized innate immunity activation (such as interferon production) or saturation of the exportin-5 pathway was observed. Overall, our data suggest constitutive expression of shRNA results in accumulation of mature shRNA molecules, inducing cellular toxicity at late time points, despite the presence of gene silencing.

UR - http://www.scopus.com/inward/record.url?scp=83455169276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455169276&partnerID=8YFLogxK

U2 - 10.1089/hum.2010.234

DO - 10.1089/hum.2010.234

M3 - Article

C2 - 21780944

AN - SCOPUS:83455169276

VL - 22

SP - 1483

EP - 1497

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -